Jiangsu Hengrui Medicine Co., Ltd.
About Jiangsu Hengrui Medicine Co., Ltd.
Certifications
-
FDA -
GMP
Categories
-
CN -
2015On CPHI since
-
2Certificates
-
5000+Employees
Company types
Meet us at
CPHI Frankfurt 2025
Messe, Frankfurt
28 Oct 2025 - 30 Oct 2025
Products from Jiangsu Hengrui Medicine Co., Ltd. (100)
-
Product Sevoflurane Inhalation Anesthetic
Sevoflurane is a sweet-smelling, nonflammable, highly fluorinated methyl isopropyl ether used as aninhalational anaesthetic for induction and maintenance of general anesthesia.
Strength: 250ml.
Sevoflurane Inhalation Anesthetic was approved by NMPA and launc... -
Product Desflurane for inhalation
Desflurane is a highly fluorinated methyl ethyl ether used for maintenance of general anesthesia.
Strength: 240ml
It is approved by NMPA.
It is approved by US-FDA and EU.
-
Product Dexmedetomidine HCl Injection
Dexmedetomide HCl is an anxiolytic, sedative, andanalgesic medication.
Strength: 200mcg/2ml (100mcg/ml); Single-dose Vial
This product has been approved by CFDA and US-FDA.
Strength: 80mcg/20ml; 200mcg/50ml; 400mcg/100ml
This product has been app... -
Product Atracurium Besylate
Atracurium besylate is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxatio... -
Product Butorphanol Tartrate
Butorphanol Tartate is a morphinan-type synthetic opioid analgesic.
It is approved by NMPA. -
Product Salmeterol xinafoate + Fluticasone propionate
It is indicated for asthma.It is still in R&D stage. -
Product Sugammadex Sodium
Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery in adults.It is still in R&D stage and estimated to be approved by 2020. -
Product Paricalcitol
Paricalcitol is a synthetic vitamin D analogue. Paricalcitol has been used to reduce parathyroid hormone levels. It is still in R&D stage, and estimated to be approved by 2020. -
Product Ondansetron
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.It is still in R&D stage and estimated to be approved by 2020. -
Product Febuxostat
Febuxostat is a xanathine oxidase (XO) inhibitor indicated in patients with gout suffering from hyperuricemia and is used in its chronic management.It is still in R&D stage and estimated to be approved by 2020. -
Product Capecitabine
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of numerous cancers. It is a prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the body.
It is approved by NMPA. -
Product Caspofungin Acetate
Caspofungin Acetate is a lipopeptide antifungal drug. It is a member of a new class of antifungals termed the echinocandins. It works by inhibiting the enzyme (1→3)-β-D-glucan synthase and thereby disturbing the integrity of the fungal cell wall. Caspofungin was the ...
Jiangsu Hengrui Medicine Co., Ltd. Resources (1)
-
Brochure Hengrui Medicine - Company Details
Hengrui Medicine is dedicated to research, developing, and promoting innovative medicine with high quality.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance